Newron Pharmaceuticals (NWRN) Company presentation summary

Company highlights

• Proven expertise in CNS drug development, validated by global approvals for Xadago in Parkinson's disease and advanced clinical progress for Evenamide in schizophrenia.

• Management and board comprise seasoned industry leaders with backgrounds at major pharmaceutical firms.

Evenamide opportunity and differentiation

• Evenamide is a first-in-class glutamate modulator targeting core schizophrenia pathology, with potential as the first add-on therapy for treatment-resistant or poorly responding patients.

• Demonstrates broad symptom improvement, excellent tolerability, and does not require changes to existing antipsychotic regimens.

• Strong intellectual property protection extends exclusivity into the 2030s and 2040s.

Market need and commercial potential

• Schizophrenia affects 23–25 million globally, with a $23bn+ antipsychotics market and significant unmet need for effective long-term therapies.

• Up to 70% of chronic patients inadequately respond to current treatments; Evenamide is positioned as the only add-on option for clozapine-resistant cases.